A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
11/2004
11/11/2004	CA2523413A1 Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds
11/11/2004	CA2522711A1 Treating hepatocellular carcinomas using therapeutic viruses
11/11/2004	CA2519207A1 Adenovirus serotype 34 vectors, nucleic acids and virus produced thereby
11/10/2004	EP1475443A2 Vectors having enhanced expression and methods of making and uses thereof
11/10/2004	EP1475440A2 Growth differentiation factor-3
11/10/2004	EP1474687A2 Marks as modifiers of the p53 pathway and methods of use
11/10/2004	EP1474535A2 Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
11/10/2004	EP1474522A1 A method for generating engineered cells for locus specific gene regulation and analysis
11/10/2004	EP1474521A2 An herpes simplex virus complex
11/10/2004	EP1474519A2 Microorganism for genetic therapeutic treatment of proliferative diseases
11/10/2004	EP1474448A1 Rrp sequences and knockout mice and uses thereof
11/10/2004	EP1474442A2 Cytotoxic t-cell epitopes from chlamydia
11/10/2004	EP1474175A2 Agents that regulate apoptosis
11/10/2004	EP1474167A2 Novel proteins in enteroaggregative esheriachia coli (eaec) useful for diagnosis and therapy of eaec infections
11/10/2004	EP1474153A2 Methods for particle-assisted polynucleotide immunization using a pulsed electric field
11/10/2004	EP1474067A2 One dose vaccination with i mycoplasma hyopneumoniae /i
11/10/2004	EP1425045A4 Adenoviral vector and related system and methods of making and use
11/10/2004	EP1297119B1 Method for introducing nucleic acids and other biologically active molecules into the nucleus of higher eukaryotic cells by means of an electrical current
11/10/2004	EP1045700B1 Oral delivery of nucleic acid vaccines by particulate complexes
11/10/2004	EP1012280B1 Trimerising module
11/10/2004	EP0998301B1 Nucleic acid based immunotherapy of chronic hepatitis b infection
11/10/2004	CN1545552A Genes and proteins, and their uses
11/10/2004	CN1545521A Peptide as antagonist of VEGF receptor Flt-1
11/10/2004	CN1545424A Anti-cancer medicine comprising disintegrin genes and treating methods thereof
11/10/2004	CN1544089A DNA vaccine for preventing influenza virus infection
11/10/2004	CN1174993C VEGI, an inhibitor for angiogenesis and tumor growth
11/09/2004	US6815534 Tissue plasminogen activator-like protease
11/09/2004	US6815431 Delivering a neurotrophic formulation comprising a neurotrophin encoding lentiviral expression vector, into one or more delivery sites within a region of the brain containing targeted neurons expressed for therapy of brain disorder
11/09/2004	US6815430 Gene expression base sequences for therapeutic use and drugs for gene therapy
11/09/2004	US6815429 Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
11/09/2004	US6815420 Methods of using chemokine beta-6
11/09/2004	US6815415 Diagnosis and treatment of malignant neoplasms
11/09/2004	US6815200 Modified adenovirus containing a fiber replacement protein
11/09/2004	US6815180 Human cervical cancer 1 protooncogene and protein encoded therein
11/09/2004	US6814964 Supramolecules containing binding and therapeutic molecules bound to hybridized nucleic acids
11/09/2004	US6814962 Defective recombinant adenovirus comprising a nucleic acid sequence coding for a biologically active human lipoprotein lipase
11/04/2004	WO2004094988A2 Tolerance to graft prior to thymic regeneration
11/04/2004	WO2004094649A2 Tolerance to graft following thymic reactivation
11/04/2004	WO2004094642A2 Lentiviral vectors carrying synthetic bi-directional promoters and uses thereof
11/04/2004	WO2004094610A2 Wnt as a factor for cardiac myogenesis
11/04/2004	WO2004094606A2 COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOPOIETIN 1 AND 2 AND THEIR RECEPTOR TIE2
11/04/2004	WO2004094605A2 Methods and compositions for inhibiting stat signaling pathways
11/04/2004	WO2004094599A2 Disease prevention and vaccination following thymic reactivation
11/04/2004	WO2004094595A2 MODIFIED iRNA AGENTS
11/04/2004	WO2004094588A2 Postnatal stem cells and uses thereof
11/04/2004	WO2004094466A2 Recombinant influenza viruses holding a mutation in a transmembrane protein gene
11/04/2004	WO2004093969A1 System for the delivery of a biologic therapy with device monitoring and back-up
11/04/2004	WO2004093920A2 Ghrh for use in treating chronic renal failure
11/04/2004	WO2004093900A1 Apoptosis inducing agent and method of inducing apoptosis
11/04/2004	WO2004093820A2 Methods and compositions for solid tumor treatment
11/04/2004	WO2004093810A2 Methods and compositions for treating disorders
11/04/2004	WO2004081167A3 Expression vectors comprising the mcmv ie2 promoter
11/04/2004	WO2004077060A3 Assay for detection of renal cell carcinoma
11/04/2004	WO2004074450A8 Combination therapy for treating protein deficiencies
11/04/2004	WO2004069194A3 Use of the oxidoreductase ncb50r for diagnosings and treating diabetes
11/04/2004	WO2004053101A3 Methods and compositions using compounds from fetal cells and tissues to improve condition of skin
11/04/2004	WO2004052177A3 Cell-based therapies for ischemia
11/04/2004	WO2004047514A3 Methods for identifying risk of breast cancer and treatments thereof
11/04/2004	WO2004043387A3 Compositions and methods for cancer diagnosis and therapy
11/04/2004	WO2004043340A3 Alpha 5 beta 1 and its ability to regulate the cell survival pathway
11/04/2004	WO2004022003A3 Materials and methods for treatment of allergic diseases
11/04/2004	WO2003102135A3 Control sequences of the human corin gene
11/04/2004	WO2003092612A3 VECTORS HAVING BOTH ISOFORMS OF β-HEXOSAMINIDASE
11/04/2004	WO2003090512A3 Regeneration of endogenous myocardial tissue by induction of neovascularization
11/04/2004	WO2003082195A3 Protamine-adenoviral vector complexes and methods of use
11/04/2004	WO2003076593A3 Genomic screen for epigenetically silenced genes associated with cancer
11/04/2004	WO2003055981A3 Methods of modulating heme oxygenase-1 expression and treating heme oxygenase-1 mediated conditions
11/04/2004	WO2002092013A3 Methods for treating liver disease and liver damage with growth hormone and foxm1b
11/04/2004	US20040220536 Apparatus with weeping tip and method of use
11/04/2004	US20040220387 Allelic nucleotide sequences for diagnosis and prognosis of bipolar affective disorder; restriction fragment length polymorphisms and disease detection
11/04/2004	US20040220132 Treatment of neurodegenerative disease through intracranial delivery of siRNA
11/04/2004	US20040220130 Compact synthetic expression vector comprising double-stranded DNA molecules and methods of use thereof
11/04/2004	US20040220126 hepatocyte growth factor gene as drug; topical applying ; side effect reduction; cardiovascular disorders
11/04/2004	US20040220125 Biosynthetic platform for cardioprotective gene expression using immature heart tissue
11/04/2004	US20040220123 therapy for bactericide infections which are drug resistance, antibiotic resistance; anticancer agents; hybrid nucleic acids;
11/04/2004	US20040220107 Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
11/04/2004	US20040220084 to cells, tissues; complexing transferrins , epidermal growth factor, endothelial growth factor to nucleic acids
11/04/2004	US20040219674 Virus envelope vector for gene transfer
11/04/2004	US20040219660 Apparatus for transfer of therapeutic agents to target tissues; tissue engineering; treatment of deep-vein thrombosis and cell proliferative disorders
11/04/2004	US20040219635 Degradation resistant antihypoxic agents for use in treatment and prevention of hypoxia and ischemic related tissue damage
11/04/2004	US20040219575 Using presence of transcription factor/tumor antigen splice variant to diagnose cell proliferative disorders; tumor cell characterization
11/04/2004	US20040219571 Genetically engineered RNA self replicating enzyme for use in removal of repetitve triplet codon associated with muscular dystrophy; gene therapeutics and RNA targeting
11/04/2004	US20040219521 Nucleotide sequences for use as tools in disease diagnostics, forensics, gene mapping, mutation identification and to assess biodiversity
11/04/2004	US20040219224 Spherical protein particles and methods for making and using them
11/04/2004	US20040219202 Pharmaceutical composition comprising lipids comprising a polar and a nonpolar moiety
11/04/2004	US20040219170 Viruses encoding mutant membrane protein
11/04/2004	US20040219169 Fusion proteins, bacteriophage capsids, cytokines, bacteriocins; attenuated, tumor-targeting Gram-negative bacterium containing a bacteriophage, wherein genome of bacteriophage has been modified to encode for gene product of interest under control of eukaryotic promoter; antitumor agents
11/04/2004	US20040219167 Herpes viruses for immune modulation
11/04/2004	US20040219165 Streptococcus pneumoniae antigens
11/04/2004	US20040219164 Advanced antigen presentation platform
11/04/2004	US20040219161 Include recombinant expression constructs containing nucleic acids encoding target cell surface receptor antigen and one or more immune response altering molecules, or the expressed products themselves
11/04/2004	US20040219152 Methods for modulating angiogenesis with apelin compositions
11/04/2004	US20040219151 Tetraspan protein and uses thereof
11/04/2004	US20040219146 Prevention and treatment of amyloidogenic disease
11/04/2004	US20040219145 Compositions and methods to modulate immune and inflammatory responses
11/04/2004	US20040219132 combining gene therapy with active site-specific chaperones to increases the stability and efficiency of the protein encoded by the recombinant gene that is administered.
11/04/2004	CA2563312A1 Plasmid mediated ghrh supplementation for renal failures
11/04/2004	CA2528503A1 Tolerance to graft prior to thymic regeneration
11/04/2004	CA2526887A1 Splice variants of human voltage-gated calcium channel alpha2delta-2 subunit designated-alpha2delta2-a and alpha2delta2-b
11/04/2004	CA2522963A1 System for the delivery of a biologic therapy with device monitoring and back-up

1 ... 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 ... 870